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Background: The clinical and etiological heterogeneity of mood disorders impede
identification of effective treatments for the individual patient. This highlights a need for
early neuronal and behavioral biomarkers for treatment efficacy, which can provide a
basis for more personalized treatments. The present systematic review aimed to identify
the most consistent neuronal and behavioral predictors of treatment efficacy on mood
symptoms and cognitive impairment in mood disorders.
Methods: We identified and included 60 original peer-reviewed studies investigating
neuroimaging and behavioral predictors of treatment efficacy within the domains of
emotional and non-emotional cognition, structural neuroimaging, and resting state
functional connectivity in patients with unipolar or bipolar disorder.
Results: Lower baseline responsivity in limbic regions coupled with heightened
medial and dorsal prefrontal responses to emotional stimuli were the most consistent
predictors of response to pharmacotherapy for depression. In contrast, heightened
limbic and ventral prefrontal reactivity to emotional stimuli seemed to predict efficacy
of psychological interventions. Early modulation of fronto-limbic activity and reduction
in negative bias were also associated with treatment response. Better performance on
non-emotional tests at baseline was relatively consistently associated with efficacy on
mood symptoms, whereas the association between neural activity during non-emotional
tests and treatment response was less clear. Other baseline factors associated
with treatment response were greater white matter integrity, resting state functional
connectivity, more prefrontal gray matter volume as well as an early increase following
short administered treatment. Finally, emerging evidence indicates that baseline cognitive
deficits are associated with greater chances of achieving treatment efficacy on cognition.
Conclusions: Patients’ profile of emotional and non-emotional cognition and
neural activity—and the early treatment-associated changes in neural and cognitive
function—may be useful for guiding treatments for depression. While cognitive deficits
at baseline seem to improve chances of treatment efficacy on cognition, more studies of
this association are urgently needed.
Keywords: mood disorders, treatment, biomarker, cognition, neuroimaging, treatment efficacy, personalized
medicine, precision medicine
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INTRODUCTION
Unipolar depression (UD) and bipolar disorder (BD) are
among top contributors to the global burden of disease, with UD
being the single largest contributor to global disability worldwide
(1). At a global level, more than 300 million people suffer from
UD and 60 million from BD (1) and the economic cost of these
affective disorders is estimated to be e113 billion in Europe
and $128 billion in the United States per year (2, 3). Despite
the major economic imperatives to optimize treatment for these
disorders, current treatment options are limited by insufficient
efficacy on depressive symptoms for 30–40% of patients, general
time lag of several months before an effective treatment can
be identified for the individual patient, and frequent residual
cognitive impairments (4–6). Specifically, cognitive impairment
has emerged as a new treatment target based on evidence for
persistent mild to moderate cognitive impairments beyond the
acute illness episodes in both UD and BD that impede patients’
functional recovery and quality of life (7, 8).
Presently, first-line treatments for mood disorders include
pharmacological treatment with selective serotonin reuptake
inhibitors (SSRI) and/or evidence-based psychotherapy, such as
cognitive-behavioral therapy (CBT) (9). However, it is often
unclear which treatment is optimal for the individual patient
until after several weeks of treatment given the delay in the
onset of response to pharmacotherapy and psychotherapy of 4–
6 weeks (10). Therefore present clinical practice and guidelines
for best treatment strategy relies on a trial and error approach
and a pragmatic advice on switching to a different treatment after
4–6 weeks of continued treatment with a therapeutic dose. As
most patients do not respond to their first prescribed treatment,
this leads to a substantial time lag of several months before an
effective treatment can be identified for the individual patient. In
this time, patients’ ability to work and function in everyday life is
severely affected, resulting in great personal and socioeconomic
costs. Notwithstanding, there is no clinically useful guideline
as to which specific treatment would be the most optimal
for the individual patient based on their particular symptom
presentation (9–11).
The clinical and etiological heterogeneity of patients with
mood disorders implicates distinct pathophysiological profiles
for each individual patient (12, 13). This highlights a pressing
need for identification of biomarkers of treatment efficacy
that can serve as a platform for personalized treatments. A
major focus of recent research has therefore been to identify
associations between biological or psychological measures and
treatment response. Clinical predictors of treatment efficacy,
such as severity or depressive clinical subtypes, have so far
shown disappointing predictive value of improvement on mood
symptoms. Genetic testing, neuroimaging, psychological and
psychophysiological approaches have therefore been employed
(9, 14). In particular, identification of early predictors of
antidepressant response at neural and cognitive level seems
an essential step to more effectively personalized treatment
options (10). However, the findings from the large number of
neuroimaging and behavioral studies of efficacy markers vary,
and there is no clear understanding of what are the most
robust neurocognitive biomarkers of treatment efficacy on mood
symptoms.
More recently, studies have begun to investigate treatments
that directly target residual cognitive impairments in mood
disorders. Specifically, recent studies have found global or
selective cognitive difficulties in 50–70% remitted patients with
mood disorders, and poorer quality of life, more stress and
impaired work capacity in cognitively impaired patients relatively
to those who are “cognitively intact” (8). While there is currently
no clinically available treatment for cognitive impairment in
mood disorders, there is strong preliminary evidence for
several candidate treatments including, modafinil, vortioxetine,
erythropoietin, lurasidone and cognitive remediation (15–20).
Nevertheless, treatment development targeting cognition is
hampered by the lack of insight into the neurobiological
underpinnings of cognitive improvement and lack insight into
baseline predictors of efficacy on cognition.
Taken together, there is a need for insight into what are the
most robust biomarkers of treatment efficacy onmood symptoms
and cognition to aid more effective, personalized treatments.
The aim of the present systematic review is therefore to
provide a “landscape” view of putative functional and structural
neuroimaging and behavioral predictors of treatment efficacy on
depressive symptoms and cognition in mood disorders. Based
on this, a discussion will be formed on the identified putative
biomarkers and how they may be integrated in the clinical
assessments of patients to aid speed and efficacy of future
treatment strategies.
METHODS
Selection Criteria
The initial search criteria were defined in accordance to
PICO framework (Population, Intervention, Comparison,
Outcome). We included original peer-reviewed articles
involving predictive intervention studies on patients with
a mood disorder (unipolar or bipolar disorder) and no
comorbid schizophrenia/schizoaffective disorder. The primary
criterion was a focus on prediction of treatment response or
remission using either neuroimaging (fMRI or MRI) or objective
neurocognitive testing as a measure. We excluded articles
that were naturalistic in design with no control of treatment;
involved pediatric, adolescent or geriatric participants; only
assessed cognitive measures with subjectively informed ratings;
only looked at single drug administrations (with no follow-up
of treatment efficacy following longer term treatment). Other
reasons for exclusion were: other languages than English;
meeting abstract, case report or study protocol; animal studies;
comorbid schizoaffective disorder.
Search Strategy
A systematic computerized search was performed on
PubMed/MEDLINE, EMBASE and PsychInfo databases from
inception up until October 2017. The search profile included
three elements: “biomarker,” “neuroimaging OR cognition”
and “mood disorder AND therapy/treatment” with each their
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combinations in the respective databases (see supplementary
material for more details).
Two of the authors (IS and HLK) independently performed
a primary title/abstract screening for potentially eligible
articles and, following this, a secondary full-text screening
was conducted. In both primary and secondary screening,
we considered each of the unique references according to
inclusion/exclusion criteria, but only provided information on
the specific reasons for exclusion of papers in the secondary
screening. Finally, a hand search was performed by tracking and
screening the citations of the included articles for possible extra
inclusions. Agreement between the two authors who performed
the screening (IS and HK) was good (primary: 94%, secondary:
87%), and any disagreements were discussed and consensus was
reached in all cases. This systematic review has followed the
procedures of the Preferred reporting items for systematic reviews
and meta-analysis (PRISMA) statement (21), and a PRISMA
flowchart can be seen in Figure 1.
RESULTS
The initial screening identified 2030 articles (duplicate hits
excluded). Out of these, 158 articles were included for
titles/abstracts screening, resulting in 89 full-text articles
evaluated for eligibility. Of these, 60 met inclusion criteria
and were included in this review. In total, 58 studies explored
different predictors of treatment efficacy on mood symptoms:
26 investigated “hot” (emotional) cognition with behavioral
and functional neuroimaging measures, 15 investigated
neuroimaging and behavioral measures of “cold” (non-
emotional) cognition as predictors of treatment response on
mood symptoms, ten investigated resting-state functional
neuroimaging measures, and eight investigated structural
neuroimagingmeasures. Only two studies investigated predictors
of treatment efficacy on cognition using demographic variables
and behavioral measures of cognition.
Emotional Cognition to Predict Treatment
Response on Mood Symptoms
The 26 studies of “hot” cognition as a putative biomarker of
treatment response examined behavioral and neuroimaging
measures of facial emotion processing and regulation, implicit
processing of emotion pictures, emotional self-referential
processing, and reward processing (see Supplementary Table 1
for study details).
Behavioral Measures of Emotion Processing
Only one published study to date examined early change in
behavioral assays of emotion processing as a predictor of
subsequent treatment response (22). The study revealed that
early increase in the recognition of happy facial expressions
in the first 2 weeks of treatment with the SSRI citalopram or
the SNRI reboxetine predicted clinical improvement indicated
by reduction in total score on Clinical Outcome in Routine
Evaluation (CORE). In contrast, early treatment-associated
improvements in the recognition of disgust and surprise were not
associated with treatment response.
Neuroimaging Data on Emotion Processing
Neural response to emotional faces
Fourteen studies explored whether treatment response was
associated with baseline neural activity to emotional faces or with
the early effects of treatment on neural response to emotional
faces in UD or BD (23–36).
Overall, the studies found that those patients who went
on to respond to antidepressant treatment (i.e., treatment
responders) exhibited amygdala hypo-activity to negative facial
expressions at baseline compared to healthy controls (32, 34).
Further, one study compared responders to healthy controls
and specified that the association between baseline amygdala
hypo-activity to facial emotions signaling reward and threat and
treatment response was independent of medication type (SSRIs
escitalopram or sertraline vs. SNRI venlafaxine). In keeping
with this, the study reported an association between amygdala
hyper-activity to sad facial expression and non-response to
venlafaxine compared to healthy controls (32). One study found
that this association between amygdala hypo-activity to sad
faces and subsequent treatment response to the anticholinergic
antidepressant scopalomine could only be observed when
patients were required to attend to the faces (i.e., instructed
to focus explicitly on the faces’ portion of the picture) in the
presence of meaningful distractor stimuli (34). Consistent with
this, one study reported that lowered baseline activity in middle
occipital cortex (i.e., visual processing area) during encoding and
recognition of faces with (task-irrelevant) emotional expressions
was associated with better treatment response to scopalomine
(29). Notably, Redlich et al. (36) did not find any significant
predictors of treatment response to electroconvulsive therapy
(ECT), though reported that both treatment groups (ECT and
pharmacotherapy) showed increased amygdala reactivity to sad
faces at baseline compared to healthy controls.
Studies have also found consistent associations between
responses to either drug treatment or chronotherapy
(combinations of repeated total sleep deprivation and light
therapy) and baseline prefrontal activity in UD and BD
(23, 27, 31). Specifically, UD responders to SSRIs fluoxetine
or sertraline exhibited greater anterior cingulate cortex (ACC)
response to fearful, angry and sad faces compared to non-
responders (23, 30, 31). In keeping with this, BD-I responders to
chronotherapy showed greater ACC andmedial prefrontal cortex
(MPFC) response during implicit processing of fearful and angry
facial expressions compared to non-responders (31). Further,
greater dorsomedial PFC (DMPFC) and posterior cingulate
cortex (PCC) response to sad faces in UD was associated with
better response to treatment with the noradrenergic and specific
serotonergic antidepressant (NaSSA) mirtazapine or venlafaxine
(27).
Finally, three studies reported an association between greater
functional connectivity (FC) (i.e., closer to healthy controls)
and treatment response to chronotherapy or pharmacotherapy
(26, 31, 35). In particular, two studies found that responders to
either chronotherapy or SSRI showed greater baseline activity
and FC within fronto-limbic networks during implicit processing
of fearful and angry faces (31, 35). In accordance with this,
responders to either venlafaxine or mirtazapine had increased
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FIGURE 1 | PRISMA flow-chart.
FC of the orbitofrontal cortex (OFC) in the left precentral gyrus
and internally within the right middle OFC during an emotional
face-matching task at baseline (26).
Notably, two studies of CBT revealed the opposite
association between baseline neural activity and treatment
response (24, 25). Specifically, responders to CBT displayed
lower dorsal ACC (DACC) activity to sad faces at baseline
compared to non-responders (24). In fact, responders’
DACC response to sad faces was more “normal” (i.e.,
more similar to the activity in healthy controls) than non-
responders’. Moreover, one study reported that the FC during
processing of sad faces at the lowest and highest intensities
identified patients who had a full clinical response to CBT
(25).
Only a few studies (all conducted on patients with UD)
explored whether early changes in neural response to emotional
faces can predict subsequent treatment efficacy (28, 29, 33).
Nevertheless, these studies provide consistent evidence for
early modulation of limbic-subcortical-prefrontal brain networks
being predictive of subsequent treatment efficacy. One study
found that early treatment-related decrease (toward normal
levels) in ACC, insula, amygdala, and thalamus reactivity to
fearful faces after 1 week characterized responders vs. non-
responders to escitalopram (33). In contrast, responders to the
SSRI paroxetine showed an early treatment-related decrease
in amygdala response to negative faces (relative to baseline)
compared to non-responders, as well as an increase in lower
dorsal regions (DLPFC and DMPFC) to negative faces (toward
“normal” levels) after six weeks of treatment relative to non-
responders (28). This suggests that paroxetine exposure over
time improves dorsal prefrontal regulation of abnormal limbic
activity. Another study found that following short-term (1 week)
scopalomine administration, responders exhibited increased
response (closer to “normal”) in bilateral middle occipital cortex
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(relative to baseline) during encoding and recognition of faces
with (task-irrelevant) emotional expressions (29).
Neural response to emotional pictures
Five fMRI studies investigated the predictive value of baseline
neural activity during emotional reactivity and emotional
regulation using emotion-laden picture stimuli for efficacy of
pharmacotherapy in UD (37–41). Responders to a combination
treatment with fluoxetine and antipsychotic olanzapine or to
venlafaxine were characterized by greater baseline activity to
negative images in the ACC and premotor cortex and to positive
images in the posterior cingulate gyrus and precuneus than non-
responders (37, 40). Further, lower ventrolateral PFC (VLPFC)
activity at baseline during attempts to suppress positive emotions
elicited by pleasant pictures was associated with greater reduction
in anhedonia after venlafaxine or fluoxetine treatment (38).
Finally, a study of CBT found that greater pre-treatment activity
in the DLPFC and anterior temporal lobe (ATL) to negative
images and to pictures in general (emotional and neutral)
predicted symptom improvement after CBT (39).
Only one study investigated the predictive value of early
changes in neural activity in response to the mood-stabilizer
lithium or the atypical antipsychotic quetiapine for subsequent
treatment efficacy (41). Patients with BD-I who later achieved
remission exhibited an early increase in MPFC, temporal, and
posterior cortical areas to emotional (unpleasant) pictures after
1 week of either lithium or quetiapine treatment. Also, while
amygdala activity at baseline and after short-term treatment
administration did not predict treatment remission, non-
remission was associated with baseline hypo-activity in the
amygdala in comparison to healthy controls and remitted
subjects (41).
Neural response during emotional self-referential processing
Four fMRI studies explored the predictive value of neural
response during emotional self-referential processing at baseline
(i.e., in which patients were instructed to judge the personal
relevance of a picture or word) (42–45). Delaveau et al. (45) found
that UD remitters to treatment with the atypical antidepressant
agomelatine (melatonin and serotonin receptor antagonist)
displayed lower baseline activation in the rostral DMPFC, PCC,
and DLPFC during self-referential processing of emotional and
neutral pictures compared to non-remitters. Consistent with this,
Miller et al. (44) found that UD responders to escitalopram
displayed lower baseline responses to negative self-referent words
in midbrain, DLPFC, paracingulate, ACC, thalamus and caudate
nuclei compared to non-responders.
Two studies of baseline neural activity predictors for
response to CBT revealed a somewhat different pattern
(42, 43). Specifically, patients with amygdala hyper-activity
and low subgenual ACC (sgACC) reactivity during self-
referent processing of negative emotional words displayed the
most improvement after CBT (42, 43). In addition sgACC
activity remained low for patients in remission after treatment,
suggesting that successful treatment did not operate by
normalizing this mechanism but rather by remaining more
like healthy individuals from pretreatment to posttreatment
measurements (43). Notably, no studies of self-referent
processing explored the association between early neural activity
changes and subsequent clinical improvement in response to
pharmacological or psychological interventions.
Neuroimaging and behavioral measures of reward processing
Two studies of reward processing as a putative biomarker
for response to behavioral activation therapy for depression
(BATD) (46, 47) found that neural response to monetary awards
at baseline was predictive of treatment efficacy. Specifically,
increased frontostriatal connectivity during reward anticipation
and increased capacity to sustain ACC activity when receiving
rewards, were found to be associated with greater treatment
response (46, 47). Consistent with this, Carl et al. (46) reported
that greater change in reaction time during reward trials (i.e.,
faster response at run 2) at baseline predicted treatment response.
Interim Summary
In sum, responders to pharmacotherapy tend to be characterized
by heightened PFC top-down control as well as greater
recruitment of ACC and/or lowered limbic and visual cortical
reactivity during the processing of emotional stimuli than non-
responders. Accordingly, particularly less limbic and occipital
reactivity to task-irrelevant emotional aspects of faces in
preference for cognitively demanding tasks was associated
with better antidepressant efficacy. In contrast, responders to
psychological interventions seem to be characterized by a
pattern of greater baseline limbic reactivity, less PFC response to
emotional stimuli and greater neural response to reward stimuli.
Additionally, the small number of studies investigating change
in neural activity after 1–6 weeks of pharmacological treatment
consistently indicate that treatment-related reduction in limbic
activity and increase in DPFC top-down control to negative
valence emotional stimuli are putative early predictors of
response to distinct biological interventions.
Non-emotional Cognition to Predict
Treatment Response on Mood Symptoms
A total of 13 studies investigated “cold” cognition as a putative
biomarker for treatment response on mood symptoms (see
Supplementary Table 2 for study details). Five studies assessed
neuroimaging measures, while eight studies examined purely
behavioral assays of non-emotional cognition as biomarkers of
treatment efficacy (7, 15, 48–58).
Combined Neuroimaging and Behavioral Measures of
Non-emotional Cognition
Five studies used a combination of neuroimaging and
neurocognitive assessment to investigate baseline predictors for
treatment response on mood symptoms in patients with UD
(51, 52, 55, 57, 58). Two studies of inhibitory control found
that aberrant neural activity within prefrontal regions during
a parametric Go/No-go task predicted subsequent treatment
efficacy. In one study, patients who responded well to duloxetine,
escitalopram or citalopram treatment showed more unsuccessful
inhibition (i.e., more performance errors) at baseline as well as
less recruitment (i.e., lower activation) of brain areas important
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for cognitive control and/or interference resolution, including
the ACC, left VMPFC and right VLPFC (58). In contrast, the
other study found that greater rostral ACC activation during
unsuccessful inhibition was associated with subsequent treatment
response (51).
Two studies of patients with UD found an association
between aberrant neural activity during verbal working memory
and clinical response to fluoxetine and rTMS, respectively (52,
57). Specifically, the fluoxetine study reported lower DACC
during verbal n-back working memory at baseline in responders
vs. non-responders (52). In contrast, the rTMS study found
that responders displayed a combination of lower activity in
perigenual, medial OFC, and middle frontal cortices, and a
greater activation in the ventral-caudal putamen during a word-
generation task at baseline compared to non-responders (57).
Notably, a third study (55) found no significant associations
between treatment response to rTMS and structural or behavioral
measures at baseline.
Behavioral Measures of Non-emotional Cognition
Seven studies explored purely behavioral assays of non-emotional
baseline cognition (i.e., performance accuracy and speed)
as potential predictors of treatment response on depression
symptoms in patients with UD and BD (7, 15, 48–50, 53, 54).
Four studies reported that better cognitive performance across
several domains predicted response to antidepressant treatment
(7, 48, 50, 53). In particular, two studies of UD patients found that
responders to fluoxetine displayed better baseline performance
in executive functioning and mental processing speed than
non-responders (48, 50). The third study showed that greater
attention performance at baseline was associated with better
clinical outcome in UD patients treated with agomelatine (7).
Finally, the fourth study found that UD and BD patients with less
over-general memory (i.e., lack of memory for specific episodes,
which is a key feature of depression) recovered faster from
depression and were at lower risk for relapse after ECT (53).
In contrast, one study found that poor cognitive performance
predicted subsequent clinical response. Specifically, UD
responders to the new norepinephrine–dopamine reuptake
inhibitor bupropion displayed visual memory deficits and slowed
mental processing speed at baseline (15).
Finally, two studies showed that a combination of high and
low performance within different cognitive domains predicted
treatment response to SSRIs (49, 54). In particular, one
study found that a combination of good sustained attention
performance and poor psychomotor speed and planning
performance predicted response to fluoxetine (54). A similar
pattern of good cognitive performance on “simple” tasks
and poor performance in “complex” tasks (requiring more
demanding effort and maintenance) was observed in responders
vs. non-responders to SSRI (drug not specified) (49).
Only one study investigated early change in cognition as a
biomarker for treatment response in patients with UD and BD
(56). This study revealed that early improvement in visuospatial
memory after 2–3 weeks of rTMS treatment predicted eventual
treatment response. Interestingly, the initial cognitive changes
appeared to be independent of antidepressant efficacy, since
patients’ cognitive improvement occurred before any mood
changes. In contrast, early treatment-related improvements in
verbal learning and memory and attention span were not related
to subsequent treatment response (56).
Interim Summary
Taken together, findings from functional neuroimaging studies
highlight aberrant neural activity during non-emotional
cognition tasks as a putative prognostic biomarker. The most
consistent marker of treatment response seems to be less
recruitment of dorsal PFC during cognitive performance.
Studies of behavioral performance measures on non-emotional
cognitive tests in UD and BD patients provided more consistent
findings. Specifically, it was demonstrated in several studies
that high performance across attention, executive function, and
memory tests was a predictor of response to pharmacological
interventions (SSRI and SNRI), rTMS, and ECT for depression
(7, 48, 50, 53). Additionally, a couple of other studies found that
a combination of good performance on simple tests and poor
performance on complex tests might predict treatment efficacy
(49, 54).
Combined Emotional and Non-emotional
Cognition to Predict Mood Improvement
Two studies investigated whether a pattern of emotional and
non-emotional cognitive performance could be used to identify
the individual patients who would achieve clinical remission
in response to escitalopram, sertraline, or venlafaxine (11,
59) (see Supplementary Table 3 for study details). Using a
novel pattern classification analysis, Etkin et al. (59) and
colleagues showed poorer treatment outcomes for a subgroup of
depressed participants (approximately one-quarter of patients)
with impairment across most cognitive and emotional capacities.
High task performance predicted remission after escitalopram
treatment (but not other medications) with 72% accuracy. The
other study investigated whether predictions of remission could
be made with a larger cognitive assessment battery, including
eight non-emotional tests tapping into several cognitive domains
and one emotional identification test (11). The study reported
that the test battery thresholds established a negative predictive
value of≥80%, which identified 41% of participants not remitting
on escitalopram, 77% of participants not remitting on sertraline,
and 39% of participants not remitting on venlafaxine (all
including 20% false negatives). These findings provide promising
ways to predict treatment efficacy with a high sensitivity and
specificity for each individual patient, although replication is
needed to establish an applicable tool for clinical use.
Resting State Functional Connectivity to
Predict Treatment Response on Mood
Symptoms
Ten studies investigated the association between resting state and
FC at baseline and treatment response in UD and BD (9, 10, 60–
67) (see Supplementary Table 4 for study details).
Four of these found that greater baseline resting-state FC in
the PFC predicted response to treatment with rTMS applied
to either DLPFC or DMPFC (60–62, 67). Specifically, Ge et
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al. (67) found that both UD and BD patients who responded
well to treatment displayed enhanced contributions to functional
connectivity, namely hyper-connectivity in ACC/VMPFC within
the anterior default mode network (DMN) and DACC/insula
within the salience network. Downar et al. (60) found that at
baseline, UD and BD responders showed increased connectivity
within reward pathways, including left VMPFC, the ventral
tegmental area, and striatum compared with non-responders.
Liston et al. (61) found that baseline hyperconnectivity between
the sgACC and multiple areas of the DMN and central executive
network independently predicted greater clinical improvements
after TMS. Finally, Salomons et al. (62) found that higher
baseline FC between DLPFC and a medial prefrontal cluster
spanning the subgenual cingulate gyrus and DMPFC was
associated with better response to treatment in UD and BD. In
addition, patients with low baseline cortico-thalamic (DMPFC-
medial dorsal thalamus), cortico-striatal (DMPFC-putamen),
and cortico-limbic (sgACC-amygdala and sgACC-hippocampus)
connectivity also experienced a greater response to the treatment
(62).
Among UD patients treated with BATD, responders were
characterized by greater baseline connectivity between the right
insula and right middle temporal gyrus (63). For UD patients
given CBT, remission was predicted by greater positive FC
at baseline with the subcallosal cingulate cortex and three
regions: the dorsal midbrain, VLPFC/insula, and VMPFC (9).
The latter study also compared patients receiving CBT with
those treated with antidepressant medications (escitalopram or
duloxetine). This revealed that negative FC (i.e., anti-correlations
of activity over time) between the same regions was associated
with remission in medication-treated patients (9). The study
thus suggests that the direction of baseline FC can be used to
predict whether an individual is more likely to benefit from
psychotherapy or pharmacotherapy. Finally, assessment of UD
patients with treatment-resistant depression (TRD) receiving
ECT (64) revealed that the brain areas in which resting-
state activity provided the largest contribution in predicting
subsequent remission were the cingulate cortex, medial- and
orbitofrontal cortices, although the direction of connectivity
(increased vs. decreased) was not specified.
Four studies of both UD and BD patients found evidence of
early change in neural activity during resting state that predicted
subsequent response to various biological treatments (10, 62, 65,
66). Specifically, efficacy of rTMS and ECT was associated with
early increase in positive/negative fronto-limbic connectivity,
respectively (62, 65). Also, another study using transcutaneous
vagus nerve stimulation (tVNS) for treatment of UD found that
treatment responders exhibited early increase in left anterior
insula activity after the first treatment session (66). In contrast,
Cheng et al. (10) found that responders to escitalopram were
characterized by early decrease in occipital cortex activity and
increase in DLPFC, DMPFC, andmiddle cingulate cortex activity
only 5 h after initial treatment administration. However, the best
predictor of clinical remission was increased activity in ACC,
midcingulate cortex, and right superior temporal gyrus (STG)
5 h after administration of escitalopram to endpoint. Moreover,
aberrant (increased and decreased, respectively) FC between
cingulate and limbic areas was predictive of response in patients
who were treated with either ECT or rTMS (62, 65).
Interim Summary
Taken together, the findings support the idea that greater positive
fronto-limbic connectivity during resting state at baseline
is predictive of treatment response to a psychotherapeutic
intervention. In contrast, decreased fronto-limbic connectivity is
predictive of response for antidepressant medication treatment.
Additionally, response to antidepressant treatment was
associated with early increase (positive and negative) in
fronto-limbic connectivity during resting state.
Structural Abnormalities to Predict
Treatment Response on Mood Symptoms
Grey Matter
Four studies investigated the association between gray matter
(GM) and treatment response in UD (23, 68–70) (see
Supplementary Table 5 for study details). Two studies found
that at baseline, decreased hippocampal volume and increased
subgenual cingulate gyrus volume, respectively, were associated
with better clinical response to electroconvulsive therapy
(ECT) (69, 70). In addition a study of patients undergoing
pharmacotherapy with fluoxetine found that greater GM volume
at baseline in the ACC, insula, and right temporo-parietal
cortex predicted faster and better symptom improvement (23).
In keeping with this, one study of patients undergoing either
pharmacotherapy with fluoxetine or CBT found that clinical
remission to pharmacotherapy was predicted by greater GM
volume density in the right rostral ACC, left PCC, whereas
no prediction was found for CBT (68). Two studies have
investigated the association between early change in GM and
treatment efficacy to ECT (69, 70). These revealed early increase
in hippocampal and amygdala volume (as well as in clinical
symptoms) that is observable already after two ECT sessions
and that this increase in volume (and the improved symptoms)
predicted subsequent response to ECT (69, 70). Redlich et al. (70)
also found increased GM volume in left hippocampus in patients
receiving ECT over time (mean 6 weeks), pointing to a reversal
of hippocampal volume loss in these patients.
White Matter
Four studies investigated whether white matter (WM) integrity
is predictive of treatment efficacy (71–74) (see Supplementary
Table 5 for study details). A study of WM integrity in BD patients
undergoing treatment with the atypical antipsychotic lurasidone
showed that greater baseline fractional anisotropy (FA) in
multiple regions, including tracts in the frontal and parietal lobes,
predicted greater reduction in depressive symptoms (74). The
other two studies investigated WM integrity in UD undergoing
treatment with escitalopram (71, 72). One study found that
remission was predicted by a pattern of higher FA in the
cingulum cingulate tract (that connects the cingulate gyrus to
the hippocampus) and lower FA in the stria terminalis tract (that
connects the hippocampus to the hypothalamus and the rest of
the limbic system) (72). The other study (71) found that lower
baseline FA in the right amygdala tracts originating from the
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mid-brain could distinguish non-remitters from remitters. The
study also showed a correlation between average FA in tracts
to the right amygdala and SSRI treatment response. One final
study examiningWM integrity in BD undergoing chronotherapy
(a combination of total sleep deprivation and morning light
therapy) observed how the degree of reduction of WM integrity
also biases the efficacy of treatment, so that clinical improvement
negatively correlated with WM integrity (73).
Interim Summary
Overall, findings from structural neuroimaging studies point to
lower hippocampal GM volume and greater ACC volume at
baseline being predictors of response to pharmacotherapy and
ECT in UD.
Non-emotional Cognition to Predict
Clinically Relevant Cognitive
Improvements
Only two studies to date have explored the impact of cognitive
performance at baseline on treatment efficacy on cognition
(18, 19) (see Supplementary Table 6 for study details). Both
were based on a randomized controlled study of erythropoietin
(EPO) treatment of patients with BD in partial remission or
with treatment-resistant UD patients. The reports revealed that
patients with cognitive dysfunction at baseline—as reflected by
cognitive performance levels that were ≥1 SD below the norm
on the targeted memory domain (18) or ≥1 on two or more
domains (19) were substantially more likely to achieve treatment
efficacy on cognition than those who were less impaired. This
was not related to simple regression toward the mean with
repeated cognitive testing since no such effect of baseline
deficits was observed in the placebo group (18). In contrast,
subjectively self-reported cognitive difficulties were only weakly
(albeit statistically significantly) associated with better chances
of achieving treatment efficacy on cognition in one (18) but not
the other study (19). Taken together these two studies highlight
the importance of baseline deficits in cognition for treatment
efficacy on cognition. However, further studies with different
interventions are necessary before any firm conclusions can be
drawn regarding the impact of baseline cognition on the chances
of treatment efficacy on cognitive impairment.
DISCUSSION
Overall Findings
There is a pressing need for insight into how we can
most effectively adapt treatments for mood disorders to the
individual patient. This systematic review identified sixty
functional or structural neuroimaging and/or behavioral studies
of baseline and early change biomarkers that were predictive
of subsequent clinical efficacy on either depressive symptoms
or cognitive impairments. An overview of the results is
presented in Figure 2. The vast majority of studies (58 of
60) focused on delineating predictors of treatment response
on depressive symptoms. The most consistent predictors of
mood improvement were heightened PFC top-down control
and greater recruitment of ACC and/or lowered limbic
reactivity to negative emotional stimuli as well as high
behavioral performance on non-emotional cognitive tests
at baseline. Specifically, lower baseline reactivity in limbic
and occipital regions coupled with greater recruitment of
dorsal and medial PFC regions seems to predict better
response to pharmacotherapy. Further, early treatment-related
increase in happiness recognition and modulation of neural
activity to negative stimuli in the cortico-limbic circuitry
were found in several studies to predict response to several
biological treatments. In contrast, greater baseline reactivity
in limbic regions and lower PFC response to negative
information, greater fronto-striatal connectivity as well as
sustained ACC activity to reward stimuli were the most
consistent predictors of response to psychological interventions.
In addition, resting state fMRI studies showed some evidence
for lower fronto-limbic connectivity at baseline and for an
early increase in fronto-limbic connectivity predicting response
to pharmacological interventions. In contrast, more positive
fronto-limbic connectivity was found in resting state fMRI
studies to predict response to psychotherapeutic interventions.
Finally, lower baseline hippocampal GM volume, greater ACC
volume and greater FA were found in structural neuroimaging
studies to predict response to pharmacotherapy and ECT, while
one study found that increased volume in hippocampus and
amygdala after only two ECT sessions predicted later clinical
response. In contrast to the large number of studies investigating
predictors of mood improvement, only two studies investigated
baseline predictors of treatment efficacy on cognition. These
randomized, controlled studies revealed preliminary evidence
for a strong association between objectively measured cognitive
deficits at baseline and subsequent clinically relevant cognitive
improvement. Notably, no published studies explored whether
improvement in cognition could be predicted by neuronal
response during cognitive testing, resting state functional
connectivity or structural neuroimaging measures.
Emotional Cognition and Resting State
Neural Activity as Biomarkers of Efficacy
on Mood
Neural responses to emotional stimuli as well as functional
connectivity during resting state seem to differentially predict
treatment response to pharmacotherapy vs. psychological
interventions and thereby aid treatment selection. For
pharmacotherapy, the studies showed the best treatment
response for patients exhibiting close to “normal” neural
responses (i.e., low limbic reactivity and high PFC top-down
control). Pharmacotherapy is hypothesized to normalize
aberrant fronto-limbic activity to emotional stimuli by reducing
the overwhelming influx of automatic negative cues early in
treatment (75). This may explain why pharmacotherapy is
more effective for patients with less aberrant neural network
dysfunction. Regarding psychotherapy, the findings support
the notion that heightened neural and cognitive reactivity (i.e.,
enhanced functional connectivity between limbic and prefrontal
regions) are predictors of treatment response. It is tempting
to speculate that patients with such greater limbic reactivity
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FIGURE 2 | An overview of identified main predictors of treatment response.
to emotional stimuli may also engage more emotionally in
psychotherapy and thereby benefit more from this type of
intervention. Further, therapy can help patients restore the
network dysfunction by strengthening their conscious PFC
top-down control through cognitive reappraisal and cognitive
restructuring of negative automatic thoughts (42, 76). This
is interesting as functional neuroimaging studies of PTSD
patients treated with CBT show that excessive fear processing
of emotional stimuli in the limbic system is associated with
poor clinical improvement (77). This is opposite to our findings
on mood disorders and therefor underlines the importance of
differentiating the profiles of the patients with affective disorders
including anxiety disorders.
Non-emotional Cognition, Neural Activity
and Structural Measures as Biomarkers of
Efficacy on Mood
Overall, the included studies reported highly consistent evidence
for better performance on non-emotional cognitive tests as
a predictor of antidepressant treatment efficacy on mood
symptoms. In addition, greater ACC volume and FA at baseline,
as well as early volume increase in limbic regions, were
predictors of response to biological treatments. Taken together,
the greater cognitive performance and PFC volume in treatment
responders may reflect greater capacity for neuroplasticity
and is consistent with evidence for a link between good
treatment prognosis and a cognitive reserve (i.e., the brain’s
capacity to compensate for neuropsychological damage and
ability tomaximize performance through recruitment of different
brain networks and cognitive strategies) (8). Notably, lower
hippocampal volume at baseline was also a predictor of
treatment response (69, 70). This is interesting since longer
duration and greater severity of depression are associated
with more hippocampal volume reduction (78, 79). In light
of these findings, the association between lower hippocampal
volume and better treatment response could suggest that
enhancement of hippocampal plasticity and neurogenesis
may be key mechanisms of antidepressant drug treatment
(80).
The findings from fMRI investigations on neural activity
during non-emotional tests were generally unclear. Specifically,
some studies found that lower task-related PFC activity during
unsuccessful inhibition as well as a verbal working memory tasks
at baseline predicted treatment response (52, 58), while other
studies found that greater task-related PFC activity predicted
treatment response (51), or that a combination of lower and
higher task-related activity at baseline were predictors (i.e.,
lower activity in perigenual, medial OFC, and middle frontal
cortices with greater activation in ventral-caudal putamen) (57).
However, the overall most consistent predictor of treatment
response seems to be lower response in prefrontal regions (in
the absence of differences in cognitive performance) suggesting
that those patients with the most efficient brain functioning (i.e.,
closer to normal with less recruitment of prefrontal resources
during cognitive testing) responded better to pharmacological
treatment. This adds to the notion that better brain function at
baseline is a predictor of treatment response. Considering this,
the discrepancies in results are likely due to the features of the
different cognitive tasks employed (e.g., tests of psychomotor
speed vs. executive functioning), as well as task difficulty,
which have considerable effects on the strength and extent
of the neural response (52). Other possible reasons for the
discrepancies are patient selection (e.g., the severity of the
depressive illness, illness course, inpatients vs. outpatients)
and treatment modalities (different medications and clinical
trial methodologies), as different pharmacological interventions
might have subtle differences in mechanisms and therefore also
different neuropsychological profiles for the responders.
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Non-emotional Cognition as an Emerging
Biomarker of Efficacy on Cognition
The emerging evidence for an association between cognitive
dysfunction at baseline and patients’ chances of achieving
treatment efficacy on cognition has potential significance for
future trials targeting cognition and for future clinical treatment
of patients’ cognitive deficits. Specifically, this association
suggests that future intervention studies may improve their
chances of demonstrating treatment efficacy by pre-screening
patients for cognitive impairments before trial entry (18, 19).
In addition, the use of a brief objective cognitive screener
seems feasible for clinical decisions regarding which patients
should be given a treatment for neurocognitive impairments
rather than mood symptoms. However, notably this evidence
comes from only two studies, and there is a remarkable
absence of research into functional and structural neuroimaging
predictors of treatment efficacy on cognition. This is a major
impediment for development of better treatment strategies to
target cognition. This issue and other major methodological
challenges in cognition trials in mood disorders were recently
addressed by a global task force of international experts in the
field under the International Society for Bipolar Disorders (ISBD)
(8, 16). The absence of insight into neuroimaging biomarkers for
efficacy on cognition impedes insight into neurobiological targets
of pro-cognitive interventions (8). Future cognition trials are
therefore encouraged to implement neuroimaging assessments
to increase our insight into the neurobiological predictors of
cognitive improvements.
Limitations
A limitation of this systematic review was that the included
studies did not consistently report on patient demographics (e.g.,
the severity of the depressive illness, illness course, inpatients
vs. outpatients), and hence these factors were not controlled
for. Also, the inclusion criterion for study design was non-
specific and did not only include randomized controlled studies,
adding to a question of study quality. Adding to this, another
methodological limitation to the present systematic review is
that only original peer-reviewed articles were included, and
a current matter in neuroimaging literature is that studies
with small sample sizes or negative results may be prone
to publication bias (81, 82). However, the present systematic
review followed the PRISMA guidelines including multiple
procedures for identification of articles, thus limiting risk of
bias (21). Nevertheless this review provides a landscape overview
of prediction biomarkers for treatment efficacy on depressive
symptoms and cognition in both unipolar and bipolar depression
by combining neuroimaging and behavioral findings. This
integrated understanding of pre-treatment and early change
biomarkers are only preliminary, though very promising andmay
have a great impact in the clinical assessments of patients to aid
in efficient treatment strategies.
CONCLUSION
In conclusion, this systematic review revealed several
promising baseline biomarkers for prediction of treatment
efficacy on mood symptoms including behavioral and neural
measures of emotional and non-emotional cognition as
well as cortico-limbic functional connectivity. The review
also highlights a need for more studies of early treatment-
related changes in these measures, since recent emerging
evidence points to informative early change in emotional
and non-emotional cognition before any clinical response
in symptom reduction. While cognition is a new important
treatment target in mood disorders, only two studies assessed
the predictors of treatment response on cognition. These
two reports found greater chances of treatment efficacy on
cognition in patients presenting objective cognitive deficits at
baseline. Nevertheless, there is a paucity of studies examining
predictors of treatment-associated cognitive improvement.
This highlights a pressing need for further investigation of
cognitive measures and associated neuronal networks that can
guide in the development of new treatment strategies targeting
cognition.
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